

**NICE Update Bulletin October 2013 for guidance issued**  
**Wednesday 23<sup>rd</sup> October 2013**

Hyperlinks to the relevant NICE web page are included, to activate link left click on your mouse. Details are also available from the NICE website (<http://www.nice.org.uk>)

<b><u>Type</u></b>	<b><u>Guidance title and reference number</u></b>
<b>Technology Appraisals (TAs)</b>	<p><a href="#">Ocriplasmin for treating vitreomacular traction TA297</a></p> <p>Ocriplasmin is recommended as an option for treating vitreomacular traction in adults, only if:</p> <ul style="list-style-type: none"> <li>• an epiretinal membrane is not present <b>and</b></li> <li>• they have a stage II full-thickness macular hole with a diameter of 400 micrometres or less <b>and/or</b></li> <li>• they have severe symptoms</li> </ul>
<b>Clinical Guidelines (CGs)</b>	<b>None published so far this month</b>
<b>Public Health Guidance</b>	<p><a href="#">Managing overweight and obesity among children and young people: lifestyle weight management services PH47</a></p> <p>This guidance aims to provide recommendations on lifestyle weight management services for overweight and obese children and young people. The recommendations cover:</p> <ul style="list-style-type: none"> <li>• planning services</li> <li>• commissioning programmes</li> <li>• core components of lifestyle weight management programmes</li> <li>• developing a tailored programme plan to meet individual needs</li> <li>• encouraging adherence</li> <li>• raising awareness of programmes</li> <li>• formal referrals to programmes</li> <li>• providing ongoing support</li> <li>• programme staff: training, knowledge and skills</li> <li>• training in how to make programme referrals</li> <li>• supporting programme staff and those making programme referrals</li> <li>• monitoring and evaluating programmes.</li> </ul>
<b>Medical Technologies Guidance</b>	<b>None published so far this month</b>

<b>NICE Quality Standards</b>	<p><a href="#">Heavy menstrual bleeding (QS47)</a></p> <p>This quality standard covers the care of women of reproductive age (including women younger than 18 years) with heavy menstrual bleeding as a result of cyclical ovarian activity or underlying uterine fibroids.</p> <p><a href="#">Depression in children and young people (QS48)</a></p> <p>This quality standard covers the diagnosis and management of depression in children and young people aged 5 up to their 18th birthday.</p>
<b>Interventional Procedures Guidance (IPGs)</b>	<p>None published so far this month</p>
<b>NICE Pathways</b>	<p>These pathways are not guidance in themselves but a way of displaying online the various guidance that exists around a subject.</p>
<b>Commissioning Guides</b>	<p><a href="#">Heavy menstrual bleeding</a></p> <p><a href="#">Depression in children and young people</a></p> <p>These guides for commissioners are issued in conjunction with NICE quality standards.</p>
<b>Diagnostics Guidance</b>	<p><a href="#">Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel DG11</a></p> <p><b>1 Recommendations</b></p> <p>1.1 Faecal calprotectin testing is recommended as an option to support clinicians with the differential diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) in adults with recent onset lower gastrointestinal symptoms for whom specialist assessment is being considered, if:</p> <ul style="list-style-type: none"> <li>• cancer is not suspected, having considered the risk factors (for example, age) described in <a href="#">Referral guidelines for suspected cancer</a> (NICE clinical guideline 27), <b>and</b></li> <li>• appropriate quality assurance processes and locally agreed care pathways are in place for the testing.</li> </ul> <p>1.2 Faecal calprotectin testing is recommended as an option to support clinicians with the differential diagnosis of IBD or non-IBD (including IBS) in children with suspected IBD who have been referred for specialist assessment, if:</p> <ul style="list-style-type: none"> <li>• appropriate quality assurance processes and locally agreed care pathways are in place for the testing.</li> </ul> <p><b>Description of the technology</b></p> <p>Several technologies that measure the level of calprotectin in stool samples (faecal calprotectin) were evaluated, including fully quantitative laboratory-based tests, fully quantitative rapid tests and semi-quantitative point-of-care tests. Faecal calprotectin is excreted in excess into the intestinal lumen during the inflammatory process and so can act as a marker for inflammatory diseases of the lower gastrointestinal tract. The tests are intended to help distinguish between inflammatory bowel diseases and non-inflammatory bowel diseases.</p>
<b>Public health briefings for local government</b>	<p>None published so far this month</p>

**Current NICE consultations with links and start and finish dates for stakeholders to make contribution**

<b>Title / link</b>	<b>Start date of consultation</b>	<b>Finish date of consultation</b>
<a href="#">Independence and mental wellbeing for older people: scope consultation</a>	27/09/2013	25/10/2013
<a href="#">Upper airways tract cancers: scope consultation</a>	27/09/2013	25/10/2013
<a href="#">Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids): appraisal consultation 2</a>	03/10/2013	25/10/2013
<a href="#">Hepatitis C: scope consultation</a>	02/10/2013	30/10/2013
<a href="#">Children's attachment: scope consultation</a>	03/10/2013	31/10/2013
<a href="#">Neonatal jaundice: quality standard consultation</a>	03/10/2013	31/10/2013
<a href="#">Non Hodgkin's lymphoma (relapsed refractory) - pixantrone monotherapy: appraisal consultation 2</a>	15/10/2013	04/11/2013
<a href="#">PH3 Prevention of sexually transmitted infections and under 18 conceptions: review proposal consultation</a>	21/10/2013	04/11/2013
<a href="#">Needle and syringe programmes (update): guideline consultation - this is an update of PH18</a>	24/09/2013	05/11/2013
<a href="#">Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty: appraisal consultation</a>	18/10/2013	08/11/2013
<a href="#">Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel): appraisal consultation</a>	18/10/2013	08/11/2013
<a href="#">Older people with long-term conditions: scope consultation</a>	15/10/2013	12/11/2013
<a href="#">Low back pain (update): scope consultation</a>	21/10/2013	18/11/2013
<a href="#">Endoscopic thoracic sympathectomy for Endoscopic thoracic sympathectomy for primary hyperhydrosis of the upper limb: interventional procedures consultation: 24 October - 21 November 2013</a>	24/10/2013	21/11/2013
<a href="#">Optical coherence tomography to guide percutaneous coronary intervention: interventional procedures consultation: 24 October - 21 November 2013</a>	24/10/2013	21/11/2013
<a href="#">Faecal microbiota transplant for recurrent Clostridium difficile infection: interventional procedures consultation 24 October - 21 November 2013</a>	24/10/2013	21/11/2013
<a href="#">Indicators process guide: Quality and outcomes framework, Clinical commissioning groups outcomes indicator set</a>	28/08/2013	30/11/2013
<a href="#">Trauma services: scope consultation</a>	13/09/2013	11/12/2013
<a href="#">Overweight and obese adults - lifestyle weight management: guidance consultation</a>	16/10/2013	11/12/2013
<a href="#">NICE future public health quality standards and guidance - proposed topic list</a>	27/09/2013	20/12/2013

**Produced by**

**Andrew Williams (Clinical Effectiveness Technical Support  
Officer) NEW Devon CCG Clinical Effectiveness and Medicines  
Optimisation Team**

**For distribution Northern, Eastern and Western Devon CCG &  
South Devon and Torbay CCG**

**County Hall, Topsham Road, Exeter, EX2 4QL**

**Tel: 01392 26 7771**

**Email: [andrew.williams6@nhs.net](mailto:andrew.williams6@nhs.net)**